Incorporating some potential obstacles arising from recent Chinese developments
15/09/23 -"Despite Philips gaining confidence, thanks to promising testing results for respiratory devices, improving operations and a big new investor coming on board, our target price resets lower due to ..."
Pages
69
Language
English
Published on
15/09/23
You may also be interested by these reports :
05/08/26
Fresenius delivered a strong Q2, with adjusted EBIT and core EPS coming in comfortably ahead of expectations and revenue broadly in line. The beat ...
03/08/26
Our TP has been cut slightly, reflecting an update to the model (net debt, and updated market parameters), with no change to the operational ...
03/08/26
Smart glasses development continues to erode margins. We will take a more conservative view of the company and revise our long-term margin ...
02/08/26
DiaSorin’s Q2 profitability surpassed expectations. Despite weak respiratory sales and challenges in China, revenue grew by mid-single digits. All ...